Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
NCT ID: NCT01366170
Last Updated: 2016-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
7 participants
OBSERVATIONAL
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01626183
Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients
NCT01623856
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
NCT01500499
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01139333
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
NCT01653613
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in anaplastic large cell lymphoma (ALCL).
* To correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (ALK) autoantibodies in patient of ANHL0131.
OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated by Western blotting, flow cytometry, and IHC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
microarray analysis
protein expression analysis
western blotting
flow cytometry
immunohistochemistry staining method
laboratory biomarker analysis
mass spectrometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of anaplastic large cell lymphoma
* Tissue microarray samples available from the Cooperative Human Tissue Network (CHTN)
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Megan S. Lim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
C.S. Mott Children's Hospital at University of Michigan Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ANHL11B1
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02860
Identifier Type: REGISTRY
Identifier Source: secondary_id
ANHL11B1
Identifier Type: OTHER
Identifier Source: secondary_id
ANHL11B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.